Tag Archives: drug

Improving nature’s own communication system to fight cancer

Our bodies are composed of trillions of different cells, which communicate with each other in order to keep us healthy. There are several ways in which messages can be sent back and forth between cells. One of

A promising novel drug for breast cancer

The reason cancer is so difficult to treat is that cancer cells are our own cells running wild, which means that they generally do not make any protein or other molecule that normal cells don’t make.  This

Neurophysiological biomarkers as a method to evaluate effects of drugs

When it comes to treatment of brain diseases not affecting the motor-system, drug development has proven difficult, because the majority of tests of drug-effects in animal experiments rely on changes in the behavior of the treated subject.

Medicines – allergic reactions to antiepileptic drugs

Around 1% of the global human population – ca. 65 million – suffer from epilepsy – a chronic neurological disease with one of the most prominent symptoms being so called epileptic seizures. With a range of antiepileptic

A transcriptomic approach for cardiac (heart) safety assessment

New drug discovery relies on several phases of safety assessment. One such prominent in vitro safety assessment assay is the “hERG potassium channel assay” for cardiac safety. If a compound blocks the hERG potassium channel in a

New systems capable of stimuli-controlled release of drugs

The search for new medical strategies with high therapeutic efficiencies and reduced adverse side-effects remains a challenge for the scientific community. The development of new drug delivery systems (DDS) to generate new solid forms of active pharmaceutical

BC007, first steps of this new drug on the way for future treatment of patients with cardiomyopathy

Dilated cardiomyopathy (DCM) is a disease of the heart in which the heart chambers stretch and thin (dilate). Under this condition, the heart and cannot pump enough blood needed by the other organs need. DCM presents as

Multiple tasks for the c-ring of the F1FO-ATP synthase

The F1FO-ATP synthase is the only enzyme in nature endowed with bi-functional catalytic mechanism of synthesis and hydrolysis of ATP. The enzyme complex is hosted in the inner mitochondrial membrane in eukaryotes and in the plasma-membrane in

Rare disease day; 500 years ago

A rare disease is a life-threatening or chronically debilitating condition with a very low prevalence. Several institutions such as Food and Drug Administration (FDA), European Medical Agency (EMA) and Therapeutic Goods Administration (TGA) have put in place

Curcumin, from Indian spice to a molecular model in drug discovery?

Nature has provided a large variety of molecules, with different degrees of complexity and therapeutic applications. Curcumin (Fig. 1) is an example of such molecules. Curcumin is a natural compound isolated from the rhizomes of the plant

Making a good drug against a bad virus better

Recent advances in the treatment of chronic Hepatitis C virus (HCV) have led to a number of treatment options using only pills taken once-a-day that can lead to the elimination of the virus – a cure. Using

Defeating cancer by taking advantage of its inbuilt frailties

The treatment of cancer is a conflicting and complex process; the drugs that are used to kill cancer cells are also toxic to your healthy tissues. However, the different physiology of tumors provides a route to deliver

Milk exosomes for drug delivery

The need to effectively deliver drugs to target site has employed a multitude of substances varying from biological to a chemical nature and solid metals for the preparation of tiny drug delivery vesicles called nanoparticles. However, factors

European Pharma Summit 2016

Organizer: GTCbio Start date: May 11th, 2016     End date: May 13th, 2016 We invite you to attend the European Pharma Summit 2016, which will take place on May 11-13, 2016 in Berlin, Germany. This event seeks to

Making drug discovery more efficient: predicting drug side effects in early screening efforts

Drug research and development is a complex and expensive process that begins with initial screening steps of candidate chemical compounds. Compounds that appear to have the desired potency against a specific cellular target or pathway are further

Evidence-based guidelines for better health: can their role be sustained?

This project matters because it recognizes a threat to the continued production or modifications (adaptation) of guidelines, which promote best health care practices; and, it offers a framework for solving this threat. Over-emphasis of unnecessarily stringent standards